BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million
Summary
BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 millionCOPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the completion of a directed share capital raise of 25,000,000 new shares at the market offer price of DKK 1.3402 per share raising gross proceeds of DKK 33,505,000 million.Jens Due Olsen, Chair of the Board, says: I am pleased to have been elected as Chair of the Board of BioPorto. The capital raise will help the company reach its objective of advancing the commercial launch of ProNephro AKI NGAL in the US and with the preparation to apply for FDA clearance of the test for adult use. By equipping clinicians with tools to detect AKI at an earlier stage, we aim to not only to save lives but also improve overall quality of life for patients affected by this condition.To receive BioPortos Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@bioporto.com, C: +45 26368918BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Companys tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.The Companys flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA.